Innoviva Price to Sales Ratio 2010-2024 | INVA
Historical PS ratio values for Innoviva (INVA) over the last 10 years. The current P/S ratio for Innoviva as of November 20, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Innoviva P/S Ratio Historical Data |
Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
2024-11-19 |
19.09 |
|
3.99 |
2024-09-30 |
19.31 |
$4.79 |
4.03 |
2024-06-30 |
16.40 |
$4.60 |
3.56 |
2023-12-31 |
16.04 |
$3.86 |
4.16 |
2023-09-30 |
12.99 |
$3.56 |
3.65 |
2023-06-30 |
12.73 |
$3.69 |
3.45 |
2023-03-31 |
11.25 |
$3.16 |
3.56 |
2022-12-31 |
13.25 |
$3.44 |
3.85 |
2024-03-31 |
15.24 |
$3.71 |
4.11 |
2022-09-30 |
11.61 |
$3.94 |
2.95 |
2022-06-30 |
14.76 |
$4.43 |
3.33 |
2022-03-31 |
19.35 |
$4.30 |
4.50 |
2021-12-31 |
17.25 |
$4.09 |
4.21 |
2021-09-30 |
16.71 |
$3.75 |
4.46 |
2021-06-30 |
13.41 |
$3.33 |
4.02 |
2021-03-31 |
11.95 |
$3.03 |
3.95 |
2020-12-31 |
12.39 |
$2.97 |
4.18 |
2020-09-30 |
10.45 |
$2.84 |
3.68 |
2020-06-30 |
13.98 |
$2.64 |
5.30 |
2020-03-31 |
11.76 |
$2.51 |
4.69 |
2019-12-31 |
14.16 |
$2.30 |
6.15 |
2019-09-30 |
10.54 |
$2.34 |
4.51 |
2019-06-30 |
14.56 |
$2.30 |
6.33 |
2019-03-31 |
14.03 |
$2.33 |
6.03 |
2018-12-31 |
17.45 |
$2.30 |
7.58 |
2018-09-30 |
15.24 |
$2.18 |
7.00 |
2018-06-30 |
13.80 |
$2.04 |
6.77 |
2018-03-31 |
16.67 |
$1.93 |
8.62 |
2017-12-31 |
14.19 |
$1.81 |
7.85 |
2017-09-30 |
14.12 |
$1.58 |
8.92 |
2017-06-30 |
12.80 |
$1.45 |
8.83 |
2017-03-31 |
13.83 |
$1.22 |
11.29 |
2016-12-31 |
10.70 |
$1.10 |
9.71 |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Large Cap Pharmaceutical |
$1.195B |
$0.310B |
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|